Neovasc Reducer System Receives Reimbursement From NHS England

June 7, 2021—Neovasc Inc. announced that the National Health Service (NHS) England has granted national reimbursement for the Neovasc Reducer system as a result of being included in the High-Cost Tariff Excluded Devices (HCTED) national catalogue. This is the first national reimbursement in European Union for the Reducer, which has received CE Mark approval for the treatment of refractory angina.

According to the company, NHS England has a nationwide purchase and supply system for specific categories of HCTED used in specialized services designed to support the accelerated adoption of effective new technologies. NHS England has agreed that these devices should be paid for separately from the national tariff for a medical procedure. Hospital providers can now order the Reducer and bill the cost of the device directly to NHS England.

Professor Jonathan Hill, MD, Consultant Interventional Cardiologist at Royal Brompton & Harefield NHS Foundation Trust in London, United Kingdom, commented in Neovasc’s announcement, “The clinical data on Reducer therapy, much of it developed in the United Kingdom, continues to demonstrate efficacy and excellent safety. Inclusion in the HCTED catalogue is an important step for Reducer therapy and will help new centers to begin utilizing the device. This is good news for the many patients suffering from refractory angina in the United Kingdom.”

Neovasc Reducer for the treatment of refractory angina has been commercially available in Europe since 2015. Reducer, which was granted FDA Breakthrough Device designation in October 2018, is not currently commercially available in the United States, advised the company.